Lysosomal Therapeutics' Series A - II Round

Lysosomal Therapeutics raised a round of funding on January 10, 2017. Investors include Allergan.

Lysosomal Therapeutics (LTI) is dedicated to small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. T…

Articles about Lysosomal Therapeutics' Series A - II Round: